Catalog No.
RHC43305
Species reactivity
Human
Host species
Mouse
Isotype
IgG2b
Clonality
Monoclonal
Tested applications
ELISA: 1:10000, FCM: 1:200-1:400, IHC: 1:200-1:1000, WB: 1:500-1:2000
Target
Pancreatic carcinoma marker protein GA733-1, Tumor-associated calcium signal transducer 2, M1S1, TROP2, TACSTD2, Cell surface glycoprotein Trop-2, GA733-1, Membrane component chromosome 1 surface marker 1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P09758
Applications
ELISA, FCM, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3B74
Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer., PMID:40446758
Assessment of trophoblast cell-surface antigen 2 (TROP2) and nectin-4 expression in choriocarcinoma., PMID:40414312
Trop2, Nectin-4, and PD-L1 expression profiles in esophageal squamous cell carcinoma: Implications for combined immunotherapy and ADC targeted therapies., PMID:40403357
LBA and LC-MS/MS based comprehensive bioanalytical methods for FDA018, a Trop-2 targeted antibody-drug conjugate., PMID:40375398
Novel TROP2 antibody-drug conjugates for treatment of HER2-negative metastatic breast cancer patients with brain metastases: a promising option☆., PMID:40359710
TROP2 expression and therapeutic targeting in uterine carcinosarcoma., PMID:40344963
Biomarkers of response to antibody-drug conjugates (TROP2 and nectin-4) and the immune microenvironment (NKG7, PD-L1, and B7-H3) in penile squamous cell carcinoma., PMID:40327767
Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma., PMID:40299780
Modular assembly and evaluation of a TROP2-targeting immunotoxin for cancer therapy., PMID:40253026
Trop-2 expression in non-small cell lung cancer., PMID:40233061
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials., PMID:40210967
Trop2-expression in primary vulvar squamous cell carcinoma., PMID:40184712
[Preparation of Trop2-Targeted CAR-T Cells Based on Nanobodies and Their Antitumor Effects Against Non-Small Cell Lung Cancer]., PMID:40109477
Preclinical evaluation of a novel antibody-drug conjugate OBI-992 for Cancer therapy., PMID:40082588
Prognostic Value of Trop-2 Expression in Nonmetastatic Triple-Negative Breast Cancer and Correlation With Emerging Biomarkers., PMID:40059728
ImmunoPET Imaging of Trop2 Expression in Bladder Cancer Using [64Cu]Cu-NOTA-Trodelvy., PMID:40059341
Noninvasive molecular imaging using anti-Trop-2 aptamer for targeted therapy of small cell lung cancer., PMID:40050871
[99mTc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Preclinical to Pilot Clinical Study., PMID:39947911
The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors., PMID:39903492
Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer., PMID:39878898
Trop2 Expression in Correlation to the Molecular Subtype in Vulvar Squamous Cell Carcinomas., PMID:39837304
OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models., PMID:39786401
Metformin-encapsulating immunoliposomes conjugated with anti-TROP 2 antibody fragments for the active targeting of triple-negative breast cancer., PMID:39775761
Assessment of targets of antibody drug conjugates in SCLC., PMID:39748112
A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan., PMID:39747638
Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes., PMID:39705501
The Tumor-Associated Calcium Signal Transducer 2 (TACSTD2) oncogene is upregulated in cystic epithelial cells revealing a potential new target for polycystic kidney disease., PMID:39666736
Sacituzumab Govitecan in Patients with Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results from the Phase II TROPiCS-03 Basket Study., PMID:39665770
[Research Progress and Perspectives of Antibody-drug Conjugates Targeting
Trophoblast Cell Surface Antigen-2 in Advanced Non-small Cell Lung Cancer]., PMID:39631833
Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models., PMID:39585341
Evaluation of trophoblast cell surface antigen-2 (TROP2) protein expression in chemotherapy-resistant and metastatic breast carcinomas., PMID:39571340
Novel Amanitin-Based Antibody-Drug Conjugates Targeting TROP2 for the Treatment of Pancreatic Cancer., PMID:39564769
Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions., PMID:39555080
Immuno-PET/CT Imaging of Trop2 with [18F]AlF-RESCA-T4 Differentiates Lung Cancer from Inflammation., PMID:39542697
Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook., PMID:39537365
Current Status and Future Prospects of TROP-2 ADCs in Lung Cancer Treatment., PMID:39525044
Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes., PMID:39500221
Antibody-drug conjugates as targeted therapy for treating gynecologic cancers: update 2025., PMID:39480912
TROP2 Expression and Therapeutic Implications in Cutaneous Squamous Cell Carcinoma: Insights From Immunohistochemical and Functional Analysis., PMID:39422290
Modulating autophagy to boost the antitumor efficacy of TROP2-directed antibody-drug conjugate in pancreatic cancer., PMID:39418963
Intraoperative evaluation of tumor margins using a TROP2 near-infrared imaging probe to enable human breast-conserving surgery., PMID:39413161
Clinicopathologic Characteristics of Trop Family Proteins (Trop-2 and EpCAM) in Gastric Carcinoma., PMID:39375055
Selection of trophoblast cell surface antigen 2-targeted aptamer for the development of cytotoxic aptamer-drug conjugate., PMID:39250993
Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors., PMID:39216478
Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back., PMID:39211043
TROP2 in colorectal carcinoma: associations with histopathology, molecular phenotype, and patient prognosis., PMID:39177576
Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial., PMID:39112464
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer., PMID:39086310
Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer., PMID:39083724
Trophoblast Cell Surface Antigen 2 Expression in Thymic Carcinoma: Brief Report., PMID:39034967
For research use only. Not for human or drug use.
